All Cancer articles
-
NewsBispecific antibody targets regulatory T cells to enhance tumour immunity
A bispecific antibody targeting CCR8 and CD3 has demonstrated the ability to deplete immunosuppressive regulatory T cells and slow tumour growth across multiple cancer models.
-
ArticleTargeting SRC-3 to reprogramme regulatory T cells in cancer
Could targeting SRC-3 in regulatory T cells help overcome tumour immunosuppression? Researchers explain how this approach could restore anti-tumour immunity and what remains to be proven in patients.
-
NewsDual-therapy approach targets TNBC energy supply in preclinical study
A combination of a CD276-targeting antibody-drug conjugate and mitochondria-disrupting gene therapy has demonstrated anti-tumour activity in preclinical models of metastatic triple-negative breast cancer.
-
NewsHidden bacterial compounds reveal potential cancer drug leads
Researchers have discovered a new family of bacterial natural products that bind the cancer-associated enzyme AKR1C3, revealing potential starting points for drug discovery.
-
NewsWhy aptamer cancer therapies are struggling to reach the clinic
Aptamers can recognise cancer-associated targets and deliver drugs directly to tumour cells. So why have so few reached the clinic? A new review examines the barriers to their development.
-
News3D Cell Painting reveals cancer drug differences missed in 2D
Two cancer drugs appeared almost identical in conventional screening, but a new 3D Cell Painting method exposed striking differences in their effects, raising questions about what 2D models might miss.
-
NewsResearchers solve 30-year mystery of key inflammatory enzyme gene
A gene responsible for producing a critical enzyme in inflammatory signalling has been identified after more than 30 years, with findings suggesting the pathway acts as both an immune alarm and a cellular shield with implications for cancer, IBD and asthma.
-
NewsBacterial microrobot platform achieves 82 percent tumour inhibition in bladder cancer
A hybrid microrobotic platform combining living bacteria, nanoparticles and targeted chemotherapy has achieved 82.4 percent tumour inhibition in preclinical bladder cancer models.
-
ArticleFinding drug targets through the noise of complex disease
The strongest disease signal may not point to the best drug target. AI could help researchers identify what matters within complex biological networks.
-
NewsVPS34 inhibition boosts GD2 visibility to enhance neuroblastoma immunotherapy
Penn State researchers have shown that inhibiting the protein VPS34 increases GD2 display on neuroblastoma cell surfaces, making tumours more visible to anti-GD2 antibodies and improving outcomes in preclinical combination studies.
-
NewsKRAS inhibition and CTLA-4 blockade could overcome gastric cancer immunotherapy resistance
Researchers have identified oncogenic KRAS as a key driver of immunosuppression in gastric adenocarcinoma.
-
NewsMathematical model reveals self-reinforcing mechanism behind HE-S2 ADC cancer therapy
A mathematical model developed by researchers from Mass General Brigham and the University of Cyprus suggests that the experimental immunomodulatory antibody-drug conjugate HE-S2 may become progressively more effective as it reduces tumour size.
-
ArticleInduced proximity drugs – why complex formation is not enough
A drug can form exactly the complex it was designed to make and still fail to work. Two recently approved induced proximity drugs show why what happens after complex formation – not formation alone – can decide the outcome.
-
NewsIn vivo CAR T review charts path to off-the-shelf cellular therapy
A review from researchers at Naval Medical University and Shanghai Jiao Tong University examines how engineering CAR T cells directly inside the body could cut manufacturing complexity and expand patient access to cellular immunotherapy.
-
NewsVaccine adjuvant AS01 shown to induce trained immunity in monocytes
A preclinical study published in Myeloid Cells reports that AS01, a vaccine adjuvant system, can induce trained immunity in human monocytes and reduce tumour growth in selected mouse cancer models.
-
ArticleHow disease exposes hidden epitopes that AI models may miss
A protein can look very different in disease without a single change to its sequence. Measuring these structural changes could reveal drug targets invisible to genomic and expression data alone.
-
NewsMayo Clinic strategy restores CAR T targets on aggressive thyroid tumours
Mayo Clinic researchers have shown that approved thyroid cancer drugs can restore a key antigen on aggressive tumour cells, making them visible once more to CAR T cells and improving treatment outcomes in preclinical models.
-
News‘Plug-and-play’ CAR T platform enables post-infusion immune cell reprogramming
City of Hope researchers have developed a modular ‘plug-and-play’ CAR T-cell platform that enables post-infusion reprogramming of engineered immune cells, offering a potential solution to treatment resistance driven by tumour evolution.
-
NewsWhat SIRPα reveals about how breast cancer takes hold in the brain
Scientists at Wake Forest University School of Medicine have uncovered a previously unrecognised cancer-intrinsic role for SIRPα in triple-negative breast cancer, linking the cell-surface protein to mitochondrial fission, tumour-cell migration and suppression of the brain’s immune defences.
-
NewsBig Picture Bio raises £2.2m to develop AI cancer combination therapies
UK-based cancer drug discovery company Big Picture Bio has closed £2.2 million in funding to advance AI-designed combination therapies into laboratory validation, using a generative world model to map complex tumour biology across disease sites and patient subgroups.